



EMERGENT®

Preparedness Today, Safer Tomorrow

FACT SHEET

FEBRUARY 2026

11

Products

\$1.04B

2024 Total Revenue

900

Employees



At Emergent, our mission is to **protect and save lives**.

At Emergent, we help prepare for today's health challenges and tomorrow's threats. For over 25 years, we've been at work preparing those entrusted with protecting public health. We deliver protective and life-saving options for health threats like smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.



PRODUCT PORTFOLIO ¹

GOVERNMENT/MEDICAL COUNTERMEASURES

ACAM2000®

(Smallpox and mpox (Vaccinia) Vaccine, Live)

Anthrasil®

[Anthrax Immune Globulin Intravenous (Human)]

BAT®

[Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]

BioThrax®

(Anthrax Vaccine Absorbed)

CNJ-016®

(vaccinia immune globulin intravenous, human)

CYFENDUS®

(Anthrax Vaccine Absorbed, Adjuvanted)

Ebanga™

(ansuvimab-zykl)

raxibacumab injection

A fully human monoclonal antibody

TEMBEZA®

(brincidofovir)

OPIOID EMERGENCY PREPAREDNESS

NARCAN® Nasal Spray 4 mg

(naloxone HCl)

KLOXXADO® Nasal Spray 8 mg

(naloxone HCl)



DEVELOPMENT AND MANUFACTURING EXPERTISE

Strategic Partnerships

Molecule-to-market services across entire drug development life cycle from clinical through commercial supply



OUR RESEARCH & DEVELOPMENT PROGRAMS ^{2,3}

Ebanga™ (Zaire ebolavirus)

TEMBELEXA® (Smallpox)

TEMBELEXA® (Mpox)

CDC CATEGORY A AGENT (Undisclosed)

CDC CATEGORY B AGENT (Undisclosed)

BARDA

BARDA

PANTHER, Africa CDC-led

Undisclosed

Undisclosed

APPROVED

APPROVED

PHASE 2

Preclinical

Preclinical

INFECTIOUS DISEASE

BIOLOGICAL THREAT

INFECTIOUS DISEASE

BIOLOGICAL THREAT

BIOLOGICAL THREAT

CORPORATE OFFICE

- Gaithersburg, Maryland

CORPORATE AFFAIRS

- Washington, DC

DEVELOPMENT SERVICES

- Gaithersburg, Maryland

SCIENCE & DEVELOPMENT

- Dublin, Ireland
- Gaithersburg, Maryland
- Winnipeg, Canada

MANUFACTURING

- Canton, Massachusetts
- Lansing, Michigan
- Winnipeg, Canada

SALES & MARKETING

- Gaithersburg, Maryland
- London, UK
- Philadelphia, Pennsylvania
- Toronto, Canada

CONTACT INFORMATION

Corporate Office

300 Professional Drive
Gaithersburg, MD 20879 USA
240.631.3200

Investor Inquiries

Richard Lindahl
EVP and Chief Financial Officer
240.631.3360
lindahlr@ebsi.com

R&D Partnership Inquiries

Christopher Alfonso
Head of R&D Strategic Partnerships
240.805.4203
alfonsoc@ebsi.com

Strategic Partnerships Inquiries

Trent Kuczynski
Director, Commercial Operations
517.993.0644
bioservices@ebsi.com

Media Inquiries

Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

EMERGENT®

Learn more at

emergentbiosolutions.com



² These product candidates have not been approved by the U.S. FDA or any other regulatory authority.
³ Status reflects both clinical and nonclinical development under the FDA Animal Efficacy Rule.

IBT - Integrated BioTherapeutics
NIAID - National Institute of Allergy and Infectious Diseases

Safe Harbor Statement

This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, our future goals and growth strategy, total contract value, the timing and results of clinical trials, development-stage programs and regulatory approvals, the intended results of our platforms and technologies, the timing of future deliverables, expansion into new global markets, and any other statements containing the words "will," "believes," "expects," "anticipates," "intends" "plans," "targets," "forecasts," "estimates" and similar expressions. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of publication, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements. Investors should consider this cautionary language as well as the information identified under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.

EBS
LISTED
NYSE

Emergent BioSolutions®, ACAM2000®, Anthrasil®®, BATO®, BioThrax®, Cyfendus®, RSDI®, NARCAN®/NASAL SPRAY, VIGIV®, TEMBELEXA® and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. Ebanga™ is a trademark of Ridgeback Biotherapeutics LP. Kloxxad® is a registered trademark of Hikma Pharmaceuticals USA Inc. All rights reserved.